Alzheimer's disease (AD) is the main cause of dementia in the elderly. Its increasing prevalence and enormous cost threaten the health and economic stability of people in the United States and many other nations. Thus, there is an urgent need to deepen our understanding of this illness and to develop better strategies to treat and prevent it. In this project, we use transgenic (tg) mouse models to study the roles of amyloid proteins and apolipoprotein (apo) E in the pathogenesis of AD. During the last funding cycle, we overexpressed human amyloid protein precursors (APPs) and APP-derived amyloid peptides (Ap)in neurons of tg mice. Similar to people with AD, APP mice showed progressive deposition of Ap in amyloid plaques and degeneration of neurons and synapses. Plaque formation depended not only on absolute levels of the fibrillogenic AfH-42 peptide but also on a number of key modifiers. High A|3l-40/Apl-42 ratios and ablation of apoE prevented neuritic plaques, whereas a,-antichymotrypsin doubled the plaque load. The cytokine transforming growth factor pi had complex effects, decreasing the overall plaque burden while promoting amyloid deposition in blood vessels. Synaptic deficits correlated with AP levels but not with plaque load, suggesting a plaque-independent role for AP in AD. Expression of apoES, but not of apoE4, prevented or delayed synaptic deficits and memory impairments in APP/apoE doubly tg mice, consistent with observations by others that apoE4 increases AD risk, accelerates AD onset, and is found in the majority of people with AD. This application follows up on our previous results, extends our project from AD pathogenesis to treatments, and addresses several important unanswered questions. We propose to determine whether nondeposited forms of AP such as Ap-derived diffusible ligands (ADDLs) cause the plaque- independent neurohal deficits we identified in APP tg mice;whether these deficits can be prevented and ameliorated by vaccination with ADDLs;whether apoE3 suppresses ADDLs more effectively than apoE4 in APP/apoE mice, tg glial cultures, and cell-free conditions;and whether transient expression of apoE3 in adult regulatable APP/apoE mice can decrease ADDL levels and inhibit neuronal deficits. We also propose to use DNA microarrays to identify additional mechanisms by which apoE isoforms might affect AP/ADDL- induced neuronal deficits. Achieving these aims could shed light on the molecular pathways that culminate in AD-associated cognitive decline and assist in the preclinical evaluation of novel treatments for the most common neurodegenerative disorder.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AG011385-17
Application #
7805530
Study Section
Special Emphasis Panel (NSS)
Program Officer
Refolo, Lorenzo
Project Start
1992-09-01
Project End
2012-03-31
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
17
Fiscal Year
2010
Total Cost
$491,343
Indirect Cost
Name
J. David Gladstone Institutes
Department
Type
DUNS #
099992430
City
San Francisco
State
CA
Country
United States
Zip Code
94158
Spencer, Brian; Kim, Changyoun; Gonzalez, Tania et al. (2016) ?-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Hum Mol Genet 25:1100-15
Rockenstein, Edward; Overk, Cassia R; Ubhi, Kiren et al. (2015) A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies. PLoS One 10:e0121570
Suberbielle, Elsa; Djukic, Biljana; Evans, Mark et al. (2015) DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. Nat Commun 6:8897
Dewji, Nazneen N; Singer, S Jonathan; Masliah, Eliezer et al. (2015) Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease. PLoS One 10:e0122451
Games, Dora; Valera, Elvira; Spencer, Brian et al. (2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci 34:9441-54
Borlikova, Gilyana G; Trejo, Margarita; Mably, Alexandra J et al. (2013) Alzheimer brain-derived amyloid ýý-protein impairs synaptic remodeling and memory consolidation. Neurobiol Aging 34:1315-27
Games, Dora; Seubert, Peter; Rockenstein, Edward et al. (2013) Axonopathy in an ?-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated ?-synuclein. Am J Pathol 182:940-53
Suberbielle, Elsa; Sanchez, Pascal E; Kravitz, Alexxai V et al. (2013) Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-?. Nat Neurosci 16:613-21
Huang, Yadong; Mucke, Lennart (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148:1204-22
Mandler, Markus; Rockenstein, Edward; Ubhi, Kiren et al. (2012) Detection of peri-synaptic amyloid-? pyroglutamate aggregates in early stages of Alzheimer's disease and in A?PP transgenic mice using a novel monoclonal antibody. J Alzheimers Dis 28:783-94

Showing the most recent 10 out of 81 publications